SCHEMBL7023299

SCHEMBL7023299

CCCCNC(=O)SCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 1/20 0.52
LIPC P11150 1/20 0.52
HTT P42858 2/20 0.51
TSHR P16473 1/20 0.51
HPGD P15428 2/20 0.51
HDAC3 O15379 1/20 0.50
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
NAAA Q02083 1/20 0.47
LMNA P02545 1/20 0.47
PAX8 Q06710 1/20 0.47
ALDH1A1 P00352 2/20 0.46
POLB P06746 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27306094 0.83 L3MBTL1 (0.54) LPLLIPCHPGDHDAC3CYP2C19
SCHEMBL6319495 0.81 IDO1 (0.51) HTTTSHRHPGDHDAC3LMNA
SCHEMBL10069499 0.77 L3MBTL1 (0.58) LPLLIPCHPGDCYP2C9CYP2C19
SCHEMBL11036049 0.76 LPL (0.61) LPLLIPCTSHRHPGDCYP2C9
SCHEMBL7079708 0.76 EPHX2 (0.48) HTTTSHRHPGDHDAC3CYP1A2
SCHEMBL14158550 0.75 L3MBTL1 (0.57) HPGDHDAC3CYP2C19ALDH1A1POLB
SCHEMBL2036620 0.75 HPGD (0.73) HPGDALDH1A1POLBCA1CA2
SCHEMBL20113451 0.74 L3MBTL1 (0.53) HDAC3CYP2C19POLBCA12CA1
SCHEMBL10069699 0.73 CA12 (0.54) TSHRHPGDALDH1A1POLBCA12
SCHEMBL2589963 0.73 MEN1 (0.58) HPGDHDAC3ALDH1A1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1537105-A Quinazolines useful as MMP-13 inhibitors ��������ʲ��������ι�˾ 2004-10-13 CN disclosed
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed
EP-0138773-B1 USE OF QUINOLINE DERIVATIVES FOR THE PROTECTION OF CROP PLANTS CIBA-GEIGY AG (CH) 1990-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 LPL 2942/4885LIPC 4424/4885HTT 3201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.